Patents Examined by M Franco G Salvoza
  • Patent number: 10525091
    Abstract: Described is the use of a parvovirus, preferably H-1PV, for the therapeutical elimination of cancer stem cells (CSCs), preferably neuroblastoma stem cells and glioblastoma stem cells.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: January 7, 2020
    Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM, RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG
    Inventors: Jean Rommelaere, Jeannine Lacroix, Joerg Schlehofer, Olaf Witt, Elisabeth Hedwig Deubzer, Sonja Kern, Christel Herold-Mende, Karsten Geletneky, Barbara Leuchs
  • Patent number: 10525072
    Abstract: The present invention discloses a method for the treatment of Flaviviridae infection that includes the administration of a 2?-branched nucleoside, or a pharmaceutically acceptable prodrug and/or salt thereof, to a human in need of therapy in combination or alternation with a drug that directly or indirectly induces a mutation in the viral genome at a location other than a mutation of a nucleotide that results in a change from serine to a different amino acid in the highly conserved consensus sequence, XRXSGXXXT (SEQ ID NO: 63), of domain B of the RNA polymerase region, or is associated with such a mutation. The invention also includes a method to detect a mutant strain of Flaviviridae and a method for its treatment.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: January 7, 2020
    Assignees: Idenix Pharmaceuticals LLC, Universita Degli Studi Di Cagliari
    Inventors: Jean-Pierre Sommadossi, Paolo La Colla, David N. Standring, Vadim Bichko, Lin Qu
  • Patent number: 10526617
    Abstract: Adeno-associated virus rh.10 sequences, vectors containing same, and methods of use are provided.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: January 7, 2020
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Guangping Gao, James M. Wilson, Mauricio R. Alvira
  • Patent number: 10526584
    Abstract: Methods are described for predicting ancestral sequences for viruses or portions thereof. Also described are predicted ancestral sequences for adeno-associated virus (AAV) capsid polypeptides. The disclosure also provides methods of gene transfer and methods of vaccinating subjects by administering a target antigen operably linked to the AAV capsid polypeptides.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: January 7, 2020
    Assignees: The Schepens Eye Research Institute, Inc., Massachusetts Eye and Ear Infirmary
    Inventors: Luk H. Vandenberghe, Eric Zinn
  • Patent number: 10508286
    Abstract: Adeno-associated virus rh.20 sequences, vectors containing same, and methods of use are provided.
    Type: Grant
    Filed: May 2, 2017
    Date of Patent: December 17, 2019
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Guangping Gao, James M. Wilson, Mauricio R. Alvira
  • Patent number: 10501758
    Abstract: A recombinant baculovirus, including: an adeno-associated virus Rep gene, an adeno-associated virus Cap gene, and an recombinant adeno-associated virus genome ITR-GOI (gene of interest) flanked by rAAV inverted terminal repeats (ITR). The ITR-GOI includes a 5? terminal nucleic acid fragment and a 3? terminal nucleic acid fragment. The ITR-GOI is linked to an expression cassette of the Cap gene and an expression cassette of the Rep gene through the 5? terminal nucleic acid fragment and the 3? terminal nucleic acid fragment, respectively.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: December 10, 2019
    Assignee: WUHAN INSTITUTE OF PHYSICS AND MATHEMATICS, CHINESE ACADEMY OF SCIENCES
    Inventors: Yang Wu, Fuqiang Xu, Xiaobin He
  • Patent number: 10493145
    Abstract: Fusion proteins comprising a carrier protein and a Human Rhinovirus (HRV) peptide, and immunogenic compositions containing such fusion proteins.
    Type: Grant
    Filed: August 17, 2018
    Date of Patent: December 3, 2019
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Guy Baudoux, Mathieu Boxus, Brigitte Colau, Martine Marchand
  • Patent number: 10495640
    Abstract: A method for diagnosing hepatitis virus infection or a hepatitis disease condition in a subject based on hepatitis virus-associated biomarkers present on exosomes in a bodily fluid sample from the subject is disclosed. Also disclosed are a method for monitoring the course of a hepatitis virus infection or a hepatitis disease condition in a subject and a method for-monitoring effectiveness of treatment to a subject with an anti-hepatitis virus agent based on hepatitis virus-associated biomarkers present on exosomes in bodily fluid samples from the subject, as well as a kit for diagnosing hepatitis virus infection and/or a hepatitis disease condition in a subject based on hepatitis virus-associated biomarkers on exosomes in bodily fluid samples from the subject.
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: December 3, 2019
    Assignee: MOREHOUSE SCHOOL OF MEDICINE
    Inventors: Gale W. Newman, Sam Anyanwu
  • Patent number: 10487309
    Abstract: Methods are generally disclosed for attaching a cell binding motif to a carboxy end of a coat protein of a Tobacco Mosaic Virus particle to form a modified-TMV particle; and attaching a cell to the cell binding motif of the modified-TMV particle. Methods are also disclosed for incorporated virus particles, e.g., TMV virus particles into hydrogels.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: November 26, 2019
    Assignee: University of South Carolina
    Inventors: Qian Wang, Lim Andrew Lee
  • Patent number: 10478490
    Abstract: This invention provides vaccines comprising two or more recombinant Herpes Simplex Virus (HSV) proteins selected from a gD protein, a gC protein and a gE protein; and methods of impeding immune evasion by HSV thereby vaccinating a subject against HSV and treating, suppressing, inhibiting, and/or reducing an incidence of an HSV infection or a symptom or manifestation thereof, comprising administration of a vaccine of the present invention.
    Type: Grant
    Filed: November 13, 2008
    Date of Patent: November 19, 2019
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Harvey Friedman, Sita Awasthi, John Lubinski
  • Patent number: 10472650
    Abstract: The present disclosure provides targeting peptides and vectors containing a sequence that encodes targetting peptides that deliver agents, to the eye. The present inventors have discovered peptides that function to target agents, such as viral vectors, to ocular cells. The present disclosure describes a method to utilize these novel peptides to direct, for example, viral capsids to the cell type of interest. In this instance, ocular cells (such as retinal cells) are targeted by the identified peptides. Vectors harboring capsid proteins modified to include such peptides can be used to provide therapeutic agents to the eye.
    Type: Grant
    Filed: February 22, 2016
    Date of Patent: November 12, 2019
    Assignee: University of Iowa Research Foundation
    Inventors: Beverly L Davidson, Yong Hong Chen, Alberto Auricchio
  • Patent number: 10463723
    Abstract: Provided herein are methods for generating dry vaccine powder formulations. Dry vaccine powder formulations can be used for intranasal delivery. Also provided are methods for stimulating local mucosal and systemic immunity by intranasal vaccine delivery.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: November 5, 2019
    Assignee: Shin Nippon Biomedical Laboratories, Ltd.
    Inventors: Ryoichi Nagata, Shunji Haruta
  • Patent number: 10456463
    Abstract: Described are vaccines having one or more antigens cholesterol and CpG. Aspects of the invention relate to the use of the vaccines of the invention for the treatment and/or prevention of human and animal disorders.
    Type: Grant
    Filed: May 27, 2011
    Date of Patent: October 29, 2019
    Assignee: Zoetis Belgium S.A
    Inventors: Heather Lynn Davis, Risini Weeratna, Paul J. Dominowski
  • Patent number: 10428112
    Abstract: The present invention provides a synthetic peptide capable of inducing an antibody to an autoantigen, and specifically, provides: a multiplexed same type-antigenic peptide having a dendritic core and B-cell recognition peptides, wherein the multiplexed same type-antigenic peptide comprises 4 to 8 B-cell recognition peptides of the same type that are bound to the terminal ends of the dendritic core directly or via a spacer, and each B-cell recognition peptide is bound to the terminal end of the dendritic core directly or via a spacer; an antibody production-inducing agent having the peptides; and a method for producing the peptide.
    Type: Grant
    Filed: June 11, 2015
    Date of Patent: October 1, 2019
    Assignees: RIKEN, Animal Allergy Clinical Laboratories Inc., Nippon Zenyaku Kogyo Co., Ltd.
    Inventors: Kenichi Masuda, Yasuyuki Ishii, Toshihiro Tsukui
  • Patent number: 10416161
    Abstract: A method for diagnosing hepatitis virus infection or a hepatitis disease condition in a subject based on hepatitis virus-associated biomarkers present on exosomes in a bodily fluid sample from the subject is disclosed. Also disclosed are a method for monitoring the course of a hepatitis virus infection or a hepatitis disease condition in a subject and a method for monitoring effectiveness of treatment to a subject with an anti-hepatitis virus agent based on hepatitis virus-associated biomarkers present on exosomes in bodily fluid samples from the subject, as well as a kit for diagnosing hepatitis virus infection and/or a hepatitis disease condition in a subject based on hepatitis virus-associated biomarkers on exosomes in bodily fluid samples from the subject.
    Type: Grant
    Filed: September 20, 2016
    Date of Patent: September 17, 2019
    Assignee: MOREHOUSE SCHOOL OF MEDICINE
    Inventors: Gale W. Newman, Sam Anyanwu
  • Patent number: 10385320
    Abstract: The present invention relates to variant AAV capsid polypeptides, wherein the variant AAV capsid polypeptides exhibit increased transduction and/or tropism in human muscle tissue or cells as compared non-variant parent capsid polypeptides.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: August 20, 2019
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Mark A. Kay, Nicole K. Paulk
  • Patent number: 10376486
    Abstract: The present invention provides compositions comprising ingenol-3-angelate (PEP005) and one or more additional latency reactivation agents. The present invention also provides methods for reactivating a latent virus in a subject infected with the virus, the method comprising administering to the subject an effective amount of ingenol-3-angelate (PEP005) alone or in combination with one or more additional latency reactivation agents. In particular embodiments, the combination of compounds advantageously provides a synergistic effect at inducing reactivation of a latent virus such as HIV.
    Type: Grant
    Filed: February 7, 2017
    Date of Patent: August 13, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Guochun Jiang, Satya Dandekar
  • Patent number: 10357558
    Abstract: The present invention relates to a method for inducing an immune response to the dengue virus, on the basis of DNA and 17D chimeric virus vaccines in combined or co-administered immunisation. The scope of the present invention also includes DNA vaccines against the four serotypes of the dengue virus, produced by forming, from each viral serotype of the dengue virus (DENV1-4), various recombinant plasmids that contain the gene that codes for the E protein, or that contain only the sequence that corresponds to the domain III of this protein. The invention also provides a vaccine composition consisting of (a) DNA vaccines against the four serotypes of the dengue virus; (b) chimeric viruses comprising the modified yellow fever vaccination virus 17D; and (c) a pharmaceutically acceptable carrier, all of which are covered by the scope of the invention.
    Type: Grant
    Filed: August 1, 2010
    Date of Patent: July 23, 2019
    Assignee: Fundacao Oswaldo Cruz
    Inventors: Ada Maria de Barcelos Alves, Adriana de Souza Azevedo, Ricardo Galler, Marcos da Silva Freire
  • Patent number: 10351605
    Abstract: The present invention relates to compositions and methods comprising chemopreventive agents that may be cupredoxin(s) or variants, derivatives and structural equivalents of cupredoxins, and at least one other chemopreventive agent. Specifically, these compositions may comprise azurin from Pseudomonas aeruginosa, and/or the 50-77 residue region of azurin (p28). The compositions of the invention may be used to prevent or inhibit the development of premalignant lesions in mammalian cells, tissues and animals, and thus prevent cancer.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: July 16, 2019
    Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
    Inventors: Craig Beattie, Tohru Yamada, Tapas Das Gupta
  • Patent number: 10352930
    Abstract: The present invention provides an immunoassay leading to the rapid and simultaneous detection of antibodies to a wide range of infectious pathogens in biological fluids of infected patients. This immunoassay involves the covalent and oriented coupling of fusion proteins comprising an AGT enzyme and a viral antigen on an identifiable solid support (e.g. fluorescent microspheres). The thus obtained antigen-coupled microspheres show enhanced capture of specific antibodies as compared to antigen-coupled microspheres produced by standard amine coupling procedures.
    Type: Grant
    Filed: July 19, 2017
    Date of Patent: July 16, 2019
    Assignee: INSTITUT PASTEUR
    Inventors: Jean-Claude Manuguerra, Jessica Vanhomwegen, Philippe Despres, Sylvie Paulous